OR WAIT null SECS
February 08, 2024
Through a €2.7 billion (US$2.9 billion) acquisition of MorphoSys, Novartis will get pelabresib, a late-stage drug candidate in development for cancer treatment.
February 05, 2024
Novo Holdings has entered into a merger agreement with Catalent and will acquire Catalent in a deal valued at $16.5 billion.
February 03, 2024
ProductLife Group has announced its acquisition of Australian company Commercial Eyes.
February 02, 2024
The industry’s M&A activity is on the up and expected to continue to rise in 2024.
February 01, 2024
With the formation of the new R&D unit, Regeneron will assume full development and commercialization rights to 2seventy bio’s preclinical- and clinical-stage cell therapy pipeline.
January 29, 2024
The acquisition adds a potential rare disease asset to Sanofi’s alpha-1 antitrypsin deficiency pipeline.
January 18, 2024
The acquisition will give Novartis full rights to CALY-002, Calypso’s lead product candidate.
January 17, 2024
The acquisition marks a pivotal expansion for the company into the US market.
January 16, 2024
Through the acquisition of Harpoon Therapeutics, Merck will gain an investigational delta-like ligand 3-targeting T-cell engager under development for cancer treatment.
January 10, 2024
Cherwell Laboratories’ cleanroom microbiology solutions will join AnalytiChem’s group of seven companies across Europe, North America, and Australia.